NewsPronto

 
Times Advertising


.

ACN Newswire

Read more press releases from ACN Newswire here

Maculus Therapeutix welcomes Privity, Prepares Capital Raise for Novel Drug Delivery Platform

  • Written by ACN Newswire

image

SANTA CLARA, CA & DUBAI, Feb 19, 2021 - (ACN Newswire) - Maculus Therapeutix, a preclinical-stage biopharmaceutical company that has developed a SINGLE injection platform to treat wet AMD (Age-related Macular Degeneration) and DME (Diabetic Macular Edema) instead of the standard 8-12 monthly injections, is pleased to welcome Privity FZ LLE as...

Read more: Maculus Therapeutix welcomes Privity, Prepares Capital Raise for Novel Drug Delivery Platform